Apeiron RIA LLC Buys 19,000 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Apeiron RIA LLC boosted its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 7.8% during the 4th quarter, Holdings Channel reports. The firm owned 262,542 shares of the biotechnology company’s stock after buying an additional 19,000 shares during the quarter. Apeiron RIA LLC’s holdings in Heron Therapeutics were worth $402,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in HRTX. The Manufacturers Life Insurance Company lifted its position in shares of Heron Therapeutics by 16.0% in the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,328 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Heron Therapeutics by 21.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 7,927 shares during the last quarter. King Wealth Management Group raised its holdings in shares of Heron Therapeutics by 52.3% during the 3rd quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 8,000 shares in the last quarter. Glenmede Trust Co. NA boosted its position in shares of Heron Therapeutics by 49.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 10,578 shares during the last quarter. Finally, Zacks Investment Management grew its holdings in shares of Heron Therapeutics by 2.4% in the third quarter. Zacks Investment Management now owns 475,575 shares of the biotechnology company’s stock valued at $946,000 after purchasing an additional 11,320 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on HRTX shares. StockNews.com raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

Heron Therapeutics Stock Performance

NASDAQ HRTX opened at $1.76 on Friday. The business’s 50 day moving average price is $1.49 and its 200-day moving average price is $1.92. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The company has a market cap of $267.69 million, a P/E ratio of -9.78 and a beta of 1.60.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same quarter last year, the firm earned ($0.17) EPS. As a group, equities analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.